News | May 09, 2012

3-D Imaging in the OR Aims to Revolutionize Radio-Guided Surgeries

May 9, 2012 — For decades, non-imaging gamma probes have been used to guide surgeons to critical lymph nodes in cancer patients. More recently, a procedure has been developed to guide tumor surgery using the same probe; however the non-imaging probes used in these procedures cannot provide accurate depth information. According to results presented by two medical institutions at the Society of Surgical Oncology 2012 Annual Cancer Symposium on March 21, the SurgicEye declipseSPECT (single photon emission computed tomography), an intra-operative handheld 3-D image-viewing device cleared by the U.S. Food and Drug Administration (FDA), may improve the accuracy of these procedures by providing 3-D images of the tumor and lymph nodes.

Leading surgeons from the Netherlands Cancer Institute in Amsterdam presented on the use of the declipseSPECT in the radio-guided resection of non-palpable breast cancer. Their results showed that declipseSPECT could support radio-guided surgery by determining the precise 3-D localization of the marked cancer and lymph nodes in the operating room. In addition, the system allowed them to determine the depth of each structure and to image the lumpectomy specimen to verify margins; all margins were verified to be negative by pathology.

“The innovative 3-D declipseSPECT technology may make the sentinel node biopsy easier and more reliable. New technologies like 3-D declipseSPECT will also open up lymphatic mapping to additional cancer types, cancer types in locations with a more intricate anatomy and cancer types with more complex lymph drainage," said lead author, Omgo E. Nieweg, the Netherlands Cancer Institute.

The team of surgeons from the general surgery department of the University Hospital of the Technische Universitat Munchen, Munich, Germany, presented on the use of the declipseSPECT in locating sentinel nodes of melanoma patients. The system enabled the physicians to intra-operatively image all of the nodes seen in pre-operative imaging. In addition, by using the device for post-excision imaging in the operating room, the team was able to confirm and document complete resection of the nodes.

The declipseSPECT device is provided in the United States exclusively by Dilon Diagnostics. “The declipseSPECT system is a natural fit for our product portfolio since it extends gamma imaging capabilities in the operating room. We are excited and encouraged by these results and our company continues to lead the molecular imaging market through innovation and partnerships like the one we share with SurgicEye,” said Dilon CEO Robert Moussa.

For more information: www.molecularbreastimaging.com, www.surgiceye.com

Related Content

New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
California Women In Favor of Extending State's Breast Density Inform Law
News | Breast Density | June 15, 2018
A recent survey of California women found that 95 percent of respondents want the state’s breast density inform law to...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Breast imaging technologies have seen a rapid evolution.

Breast imaging technologies have seen a rapid evolution.

Feature | Women's Health | June 05, 2018 | By Jeff Zagoudis
Breast imaging technologies have evolved rapidly in the last two decades to help physicians detect breast cancers at
Emerging Trends in Nuclear Medicine
Feature | Nuclear Imaging | June 04, 2018 | By Jeff Zagoudis
Nuclear imaging and its various modalities have long played an important role in the diagnosis and treatment of numer
Overlay Init